Adding cisplatin to standard gemcitabine/nab-paclitaxel drug treatment provided a very high rate of tumor shrinkage for patients with advanced pancreatic cancer, according to the results of a pilot clinical trial. These statistically significant and clinically meaningful improvements in overall response and survival rates resulted from a phase Ib/II clinical study.